NVIC Articles

June-2024

News-Overview/June-2024

Latest articles

Browse Articles

James Meehan, MD – A Brave Doctor Who Cared
Article

James C. Meehan, Jr., MD, 59, an ophthalmologist and functional medicine doctor, who was an outspoken critic of COVID-19 shot risks and failures, a brave vaccine choice advocate, and longtime...

The U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously on June 5th to recommend that the FDA update the COVID-19 vaccine to include a SARS-CoV-2 JN.1 lineage strain to replace the XBB1.5 strain.
Article

The FDA's Vaccines and Related Biological Products Advisory Committee voted to recommend updating the COVID-19 vaccine to include a SARS-CoV-2 JN.1 lineage strain, citing the current vaccine's ineffectiveness against emerging variants. Despite the absence of safety data, the committee emphasized the importance of vaccine effectiveness, while noting the potential for rapid variant evolution which might impact vaccine efficacy. Manufacturers like Moderna, Pfizer, and Novavax presented promising data for their new vaccine candidates, with an emphasis on preparedness to meet the FDA's upcoming strain decision.

Topics
Select disease / vaccine